R-biolin: 1st-in-Animal Study

In November 2024, rBIO successfully completed an animal study that demonstrated clear bioequivalence between R-biolin and Novo Nordisk’s, Novolin-R, confirming comparable pharmacokinetics and efficacy. These results mark a major milestone in R-biolin’s path toward commercialization, providing critical validation for regulatory approval and future clinical trials.